Search

everythinglearnresearchcommunity

for

Search:↓

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

AIRE deficiency causes hair loss similar to alopecia areata in mice.

An 11-year-old girl with severe hair loss was successfully treated with a new combination therapy.

Upadacitinib may effectively treat alopecia areata without side effects.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata treatment varies, with no optimal method established yet.

Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Stem cell technologies and regenerative medicine, including platelet-rich plasma, show promise for hair restoration in treating hair loss, but more research is needed.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Activating STAT5 in the skin's dermal papilla is key for starting hair growth, regenerating hair follicles, and healing wounds.

The enzyme CD73 helps control human hair growth and could be targeted to treat hair growth disorders.

Human hair follicles have a scent receptor that can influence hair growth.